
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine
MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel …
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine Read More